Cloud Adoption vs Regulatory Control
Automate evidence collection and parallelise risk-assessment workflows so procurement speed and governance quality improve simultaneously rather than trading off.
CyberTRIZ analysis · Pharma contradiction V009 · one of 8,235 worked contradictions published by CyberTRIZ.AI
Regulations
Business Context
Cloud computing has become an essential component of modern pharmaceutical operations. Software-as-a-Service (SaaS), Platform-as-a-Service (PaaS), and cloud-hosted validation platforms provide greater scalability, improved collaboration, lower infrastructure costs, and faster software deployment. Despite these advantages, pharmaceutical organizations remain fully responsible for ensuring that cloud-based systems comply with GMP, FDA 21 CFR Part 11, EU GMP Annex 11, GAMP® 5, and internal quality requirements.
The Contradiction
Cloud technologies increase flexibility and scalability. Greater cloud adoption may reduce direct organizational control over regulated systems.
Why It Exists
Many organizations incorrectly assume that responsibility for validation transfers to the cloud provider. In reality, suppliers remain responsible for infrastructure, while pharmaceutical companies remain responsible for intended use, computerized system validation, data integrity, security, and regulatory compliance.
Applying Pharmatriz
Cloud governance should combine supplier assurance with organization-specific validation. Risk-based supplier assessments, Service Level Agreements (SLAs), cybersecurity evaluations, periodic reviews, and continuous monitoring provide confidence without eliminating the benefits of cloud technologies.